|
Name |
cyclo(L-tyrosyl-L-phenylalanyl)
|
Molecular Formula | C18H18N2O3 | |
IUPAC Name* |
(3S,6S)-3-benzyl-6-[(4-hydroxyphenyl)methyl]piperazine-2,5-dione
|
|
SMILES |
C1=CC=C(C=C1)C[C@H]2C(=O)N[C@H](C(=O)N2)CC3=CC=C(C=C3)O
|
|
InChI |
InChI=1S/C18H18N2O3/c21-14-8-6-13(7-9-14)11-16-18(23)19-15(17(22)20-16)10-12-4-2-1-3-5-12/h1-9,15-16,21H,10-11H2,(H,19,23)(H,20,22)/t15-,16-/m0/s1
|
|
InChIKey |
GRWVBLRIPRGGPD-HOTGVXAUSA-N
|
|
Synonyms |
cyclo(L-Tyr-L-Phe); cyclo(L-tyrosyl-L-phenylalanyl); CHEBI:71611; CHEMBL191426; cyclo(L-phenylalanyl-L-tyrosyl); (3S,6S)-3-benzyl-6-(4-hydroxybenzyl)piperazine-2,5-dione; cyclo(Phe-Tyr); cyclo(TyrPhe); Cyclo[Phe-Tyr-]; cyclo(L-Phe-L-Tyr); (3S,6S)-3-benzyl-6-[(4-hydroxyphenyl)methyl]piperazine-2,5-dione; BDBM50505740; ZINC13376427; Q27139754; 1ED; cYF
|
|
CAS | NA | |
PubChem CID | 11438306 | |
ChEMBL ID | CHEMBL191426 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 310.3 | ALogp: | 2.3 |
HBD: | 3 | HBA: | 3 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 78.4 | Aromatic Rings: | 3 |
Heavy Atoms: | 23 | QED Weighted: | 0.803 |
Caco-2 Permeability: | -4.815 | MDCK Permeability: | 0.00002070 |
Pgp-inhibitor: | 0.004 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.871 | 20% Bioavailability (F20%): | 0.993 |
30% Bioavailability (F30%): | 0.659 |
Blood-Brain-Barrier Penetration (BBB): | 0.041 | Plasma Protein Binding (PPB): | 87.78% |
Volume Distribution (VD): | 0.496 | Fu: | 17.45% |
CYP1A2-inhibitor: | 0.072 | CYP1A2-substrate: | 0.074 |
CYP2C19-inhibitor: | 0.67 | CYP2C19-substrate: | 0.065 |
CYP2C9-inhibitor: | 0.621 | CYP2C9-substrate: | 0.87 |
CYP2D6-inhibitor: | 0.174 | CYP2D6-substrate: | 0.684 |
CYP3A4-inhibitor: | 0.708 | CYP3A4-substrate: | 0.202 |
Clearance (CL): | 7.276 | Half-life (T1/2): | 0.77 |
hERG Blockers: | 0.141 | Human Hepatotoxicity (H-HT): | 0.376 |
Drug-inuced Liver Injury (DILI): | 0.092 | AMES Toxicity: | 0.474 |
Rat Oral Acute Toxicity: | 0.615 | Maximum Recommended Daily Dose: | 0.382 |
Skin Sensitization: | 0.152 | Carcinogencity: | 0.267 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.011 |
Respiratory Toxicity: | 0.031 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001911 | 0.720 | D0H6TP | 0.447 | ||||
ENC003593 | 0.718 | D06ZPS | 0.411 | ||||
ENC004531 | 0.616 | D0S2BV | 0.403 | ||||
ENC001912 | 0.616 | D0I0DL | 0.378 | ||||
ENC004934 | 0.616 | D0Y7EM | 0.366 | ||||
ENC001909 | 0.566 | D08FTG | 0.337 | ||||
ENC003591 | 0.554 | D0L0SW | 0.336 | ||||
ENC005246 | 0.532 | D09PZZ | 0.327 | ||||
ENC002604 | 0.532 | D0U7SH | 0.322 | ||||
ENC004648 | 0.512 | D0N4OW | 0.319 |